A Phase 3, Multicenter, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% and 1.0% Compared to Vehicle in Participants With Dry Eye Disease (VELOS-4)

The objectives of this study are to compare the efficacy and safety of tanfanercept ophthalmic solution 0.25% and 1.0% to vehicle for the treatment of DED.

开始日期2024-05-01

申办/合作机构

HANALL BIOPHARMA Co., Ltd.

NCT05109702 / Completed临床3期

A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye

The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.

开始日期2021-11-18

申办/合作机构

HANALL BIOPHARMA Co., Ltd.

[+1]

CTR20202142 / Active, not recruiting临床3期

一项评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性的3期、多中心、随机、双盲、安慰剂对照研究

评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性。

开始日期2021-02-25

申办/合作机构

BINEX Co., Ltd.

[+3]

100 项与特那西普相关的临床结果

登录后查看更多信息

100 项与特那西普相关的转化医学

登录后查看更多信息

100 项与特那西普相关的专利（医药）

登录后查看更多信息

2,159

项与特那西普相关的文献（医药）

2024-03-15·The British journal of dermatology

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies

Article

作者: Alabas, Oras ; Stevenson, Matthew D ; Williams, Hywel C ; Grainge, Matthew J ; Mallen, Christian D ; Aithal, Guruprasad P ; Nakafero, Georgina ; van der Windt, Danielle A ; Warren, Richard B ; Taal, Maarten W ; Riley, Richard D ; Card, Tim ; Fox, Christopher P ; Abhishek, Abhishek ; Evans, Ian

Abstract:

Background:

There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment.

Objectives:

To evaluate the incidence and risk factors of anti-TNFα treatment cessation owing to liver, blood and renal side-effects, and to estimate the cost-effectiveness of alternate intervals between monitoring blood tests.

Methods:

A secondary care-based retrospective cohort study was performed. Data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) were used. Patients with at least moderate psoriasis prescribed their first anti-TNFα treatment were included. Treatment discontinuation due to a monitoring blood test abnormality was the primary outcome. Patients were followed-up from start of treatment to the outcome of interest, drug discontinuation, death, 31 July 2021 or up to 5 years, whichever came first. The incidence rate (IR) and 95% confidence intervals (CIs) of anti-TNFα discontinuation with monitoring blood test abnormality was calculated. Multivariate Cox regression was used to examine the association between risk factors and outcome. A mathematical model evaluated costs and quality-adjusted life years (QALYs) associated with increasing the length of time between monitoring blood tests during anti-TNFα treatment.

Results:

The cohort included 8819 participants [3710 (42.1%) female, mean (SD) age 44.76 (13.20) years] that contributed 25 058 person-years (PY) of follow-up and experienced 125 treatment discontinuations owing to a monitoring blood test abnormality at an IR of 5.85 (95% CI 4.91–6.97)/1000 PY. Of these, 64 and 61 discontinuations occurred within the first year and after the first year of treatment start, at IRs of 8.62 (95% CI 6.74–11.01) and 3.44 (95% CI 2.67–4.42)/1000 PY, respectively. Increasing age (in years), diabetes and liver disease were associated with anti-TNFα discontinuation after a monitoring blood test abnormality [adjusted hazard ratios of 1.02 (95% CI 1.01–1.04), 1.68 (95% CI 1.00–2.81) and 2.27 (95% CI 1.26–4.07), respectively]. Assuming a threshold of £20 000 per QALY gained, no monitoring was most cost-effective, but all extended periods were cost-effective vs. 3- or 6-monthly monitoring.

Conclusions:

Anti-TNFα drugs were uncommonly discontinued owing to abnormal monitoring blood tests after the first year of treatment. Extending the duration between monitoring blood tests was cost-effective. Our results produce evidence for specialist society guidance to reduce patient monitoring burden and healthcare costs.

2024-03-01·Wilderness & environmental medicine

Evaluation of Scorpion Stings in Children

Article

作者: Öz, Erdoğan ; Parlak, Mehmet Emin ; Küçükkelepçe, Osman

Introduction:

Scorpion stings are a significant public health problem in many parts of the world. Children are at a higher risk of developing severe complications from scorpion envenoming, including cardiac, respiratory, and neurologic complications. In Turkey, members of the Buthidae family are the most common culprits in severe envenoming events.

Methods:

This retrospective-descriptive study was conducted in Turkey. Children aged 0 to 18 y admitted to the emergency department of Kahta State Hospital between December 2017 and December 2020 were included in the study. Patient information was reviewed, and 78 patients with complete demographic, laboratory, and clinical data were included in the study.

Results:

Out of the 78 patients, 24.4% were six years old or younger while the 75.6% were older than six years. Alpha blocker was given to 12.8% of the patients, and antivenom was given to 43.6% of the patients. Of the 78 patients, 71.8% were followed up in the emergency department, 21.8% were followed up in the inpatient unit, and 6.4% were followed up in the intensive care unit. Two patients (2.6%) died within 1 month. There was a significant difference regarding lactate dehydrogenase value according to the sting site ( P=0.014). Lactate dehydrogenase values of patients stung on the head and neck and upper extremity were higher than those of patients bitten on lower extremities.

Conclusions:

Elevated levels of specific laboratory parameters, such as leukocytes, aspartate transaminase, and lactate dehydrogenase, are linked to worse outcomes. Additionally, stings on the head, neck, and upper extremities are more strongly associated with severity. These findings guide tailored treatment strategies for scorpion stings, with the potential for further refinement through broader studies across diverse regions and populations.

2024-02-01·Expert opinion on investigational drugs

Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis

Article

作者: Akhavanrezayat, Amir ; Thng, Zheng Xian ; Or, Christopher Chi Mong ; Shin, Yong Un ; Tran, Anh N T ; Regenold, Jonathan ; Bromeo, Albert John ; Karaca, Irmak ; Ghoraba, Hashem H ; Mohammadi, S Saeed ; Khatri, Anadi ; Than, Ngoc T T ; Nguyen, Quan Dong

INTRODUCTION:

Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract and is one of the leading causes of vision impairment. In developed countries, noninfectious uveitis (NIU) represents most cases and is challenging to treat due to its severity, chronicity, and high recurrence rates. The advent of anti-tumor necrosis factor-α (anti-TNF-α) agents have dramatically improved outcomes and changed treatment paradigms in NIU.

AREAS COVERED:

The index article summarizes the present experience of anti-TNF-α agents in NIU pharmacotherapy and highlights the barriers to further research and development of anti-TNF-α agents for uveitis. Common challenges faced in NIU clinical drugs trials, specific difficulties in anti-TNF-α drug development, and promising competitor drug candidates are discussed and evaluated.

EXPERT OPINION:

Anti-TNF-α agents have revolutionized NIU pharmacotherapy and greatly improved outcomes with good safety profiles. The great success of systemic infliximab and adalimumab in NIU treatment has resulted in little impetus for further development of this class of medication. Attempts have been made to deliver anti-TNF-α agents intravitreally but that has not been successful thus far. With expiring patents, competition from biosimilars and newer, novel molecules, it may not be viable to continue pursuing anti-TNF-α drug development.

159

项与特那西普相关的新闻（医药）

2024-06-20

·BioSpace

Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study

Pictured: Concept art showing an elderly woman overlaid with an illustration of a brain/iStock, boonstudio Drugs commonly used for the treatment of enlarged prostate may also help lower the risk of dementia with Lewy bodies, according to a new observational study from the University of Iowa Health Care. Drawing from Merative MarketScan, one of the largest proprietary U.S. healthcare claims databases, University of Iowa researchers identified more than 643,000 men who were starting treatment for benign prostatic hyperplasia with one of six common therapies. Three of these drugs fell under the class of α-1 adrenergic receptor antagonists, better known as α-blockers, which work by inhibiting the contraction of smooth muscles. The researchers focused on terazosin, which is sold by Abbott under the brand name Hytrin, doxazosin, which is marketed by Pfizer as Cardura, and alfuzosin, which is branded as Uroxatral by Sanofi. Alpha-blocker drugs are known to have a unique side effect: they activate a key enzyme involved in the production of ATP, which is the molecular form of cellular energy. In the brain, these drugs can help boost the production of energy and fight neurodegeneration, the University of Iowa scientists hypothesized. As active comparators, the researchers also followed men in Merative MarketScan who were being treated with tamsulosin or with the 5α-reductase inhibitors (5ARI) finasteride and dutasteride, all of which are not known to affect energy production in the brain. The men included in the study had no history of dementia with Lewy bodies (DLB). Participants were then followed until they exited the database or until they developed DLB. After an average follow-up of around three years, the study found that men who were initiated on the three alpha-blocker drugs were 40% less likely to develop DLB than comparators who were on tamsulosin. Compared with men whose enlarged prostates were being treated with 5ARI agents, the risk of DLBA was 27% lower in those taking alpha-blocker drugs. Both effects were statistically significant. By contrast, DLB had a statistically similar likelihood of developing in men being managed with tamsulosin and 5ARIs. These results were robust to several sensitivity analyses, according to researchers. The University of Iowa scientists published their findings Wednesday in Neurology, the medical journal of the American Academy of Neurology. “If terazosin and these similar medications can help slow this progression—if not outright preventing the disease—this would be important to preserving cognitive function and quality of life in people with DLB,” Jacob Simmering, assistant professor of internal medicine at the University of Iowa and lead study author, said in a statement. However, the researchers caution that the study is simply observational in design and only shows that there is a statistical correlation between the use of alpha-blocker drugs and the reduced risk of DLB. It does not establish causation nor does it show any directionality of association, they said. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

临床结果

2024-05-28

·PRNewswire

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies. Deal value can exceed $300 million USD for the initial product. ROCKVILLE, Md. and SEOUL, South Korea, May 28, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming. This agreement expands the relationship between the companies, which began in 2022 when HanAll made an initial investment in Turn Bio. The terms grant HanAll the right to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic disease. HanAll anticipates leveraging synergies between ophthalmic and otic fields where it has therapeutic expertise and experience, and drawing on Turn Bio's knowledge of cellular reprogramming, mRNAs, and lipid nanoparticles. Aging mitigation and cell reprogramming technologies have been gaining attention for their potential to address the high unmet needs in age-related disorders, particularly in the eye and ear. HanAll has been actively exploring cell reprogramming through open collaborations and a global network. The ERATM technology developed by Turn Bio reverses certain aspects of cellular aging by utilizing a cocktail of mRNA transcription factors specifically designed for transient epigenetic reprogramming. Past attempts at similar technologies have struggled due to the risk of cells differentiating into unforeseen cell types. Turn Bio's technology aims to overcome these challenges by restoring youthful cell function through precise dosing and timing of ERATM while maintaining the original cellular identity, offering promising potential for addressing age-related disorders. Currently, Turn Bio is undertaking pre-clinical research for dermatology and immunology applications. "We're excited to advance into a new phase of development with Turn Bio to explore the potential of its innovative platform in addressing important age-related conditions. This partnership will enhance HanAll's R&D capabilities in mRNA and LNP product development while also providing an opportunity to explore the potential for pipeline expansion," said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma. "This agreement is a testament to the vast opportunities ahead globally as the world's population grows older," said Turn Bio CEO Anja Krammer. "HanAll's commitment is recognition that our innovative ERA™ technology has the potential to revolutionize treatments for myriad conditions associated with aging." The deal, valued over $300 million USD for the first product, is structured around negotiated milestones. About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in China for the treatment of dry eye disease. HL161ANS, an anti-FcRn antibody targeting multiple indications, and HL192 (ATH-399A), a Nurr1 activator currently targeting Parkinson's Disease, are also being evaluated in Phase 1 clinical studies (healthy volunteers). For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR ([email protected], [email protected]). About Turn Biotechnologies Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ reprogramming technology aims to restore optimal gene expression by combatting the effects of aging in the epigenome. This potentially restores cells' ability to prevent or treat disease and heal or regenerate tissue and helps to fight incurable chronic diseases. Turn Bio's eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types. The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see . or contact Jim Martinez, rightstorygroup / [email protected] or +1 (312) 543-9026. Disclaimer statement The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements HanAll (the company, we) makes concerning its 2024 business and financial outlook and related plans, the therapeutic potential of its product candidates, the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts, the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. These may include various significant factors such as our expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements. In addition, performance may be affected by our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property of technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of product candidates. A further list and description of these risks, uncertainties and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations. SOURCE HanAll Biopharma

临床1期引进/卖出临床3期临床2期

2024-05-28

·PRNewswire

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

Synergistic collaboration to revolutionize age-related therapies worldwide Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions. The agreement, potentially exceeding $300 million in value for the first of multiple planned products, significantly expands the relationship between the companies. HanAll originally invested in Turn Bio in 2022. A New Frontier in Age-Related Therapies Products resulting from this collaboration will utilize Turn Bio's Epigenetic Reprogramming of Age (ERATM) technology and its novel eTurna™ delivery platform. These cutting-edge technologies aim to restore optimal gene expression, combatting the effects of aging at the cellular level to treat and potentially cure chronic conditions. "This partnership is a milestone for Turn Bio," said company CEO Anja Krammer. "With HanAll's support, we are accelerating the development of transformative therapies for eye and ear indications, which can benefit patients around the world. The potential impact on patients' lives is enormous, and this is just the beginning." HanAll has closely monitored Turn Bio's progress since its initial investment, recognizing the revolutionary potential of its epigenetic reprogramming technology. "Turn Bio's innovative approach to epigenetic reprogramming aligns closely with HanAll's mission to explore innovative medicines to expand our therapeutic area," said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma. "Together, we are poised to pioneer new treatments that address critical unmet needs, particularly in aging-related diseases." Expanding Horizons in Regenerative Medicine The partnership expands Turn Bio's development, which had primarily focused on dermatology and immunology, to two other organs most commonly affected by age-related conditions. This means Turn Bio is working on therapies to treat and potentially cure most diseases caused by aging. "The power of ERA™ technology is that it can rejuvenate cells in virtually any organ in the body," said Turn Bio Co-founder Vittorio Sebastiano, the company's head of research. "This agreement enables us to accelerate our development on multiple fronts to reverse the damage caused by aging and improve the quality of life for older patients." ABOUT TURN BIOTECHNOLOGIES Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ reprogramming technology aims to restore optimal gene expression by combatting the effects of aging in the epigenome. This potentially restores cells' ability to prevent or treat disease and heal or regenerate tissue and helps to fight incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types. The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see . About HanAll Biopharma HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in China for the treatment of dry eye disease. HL161ANS, an anti-FcRn antibody targeting multiple indications, and HL192 (ATH-399A), a Nurr1 activator currently targeting Parkinson's Disease, are also being evaluated in Phase 1 clinical studies (healthy volunteers). For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR ([email protected], [email protected]). FOR MORE INFORMATION, CONTACT: Jim Martinez, rightstorygroup [email protected] or (312) 543-9026 Logo -

引进/卖出临床3期临床1期临床2期

100 项与特那西普相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	临床3期	美国	HANALL BIOPHARMA Co., Ltd.	2019-03-10
干眼症	临床3期	-	Daewoong Pharmaceutical Co., Ltd.	-
干眼症	临床3期	-	HANALL BIOPHARMA Co., Ltd.	-
湿性黄斑变性	临床前	韩国	HANALL BIOPHARMA Co., Ltd.	2018-07-27
葡萄膜炎	临床前	韩国	HANALL BIOPHARMA Co., Ltd.	2018-07-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05109702 (CTgov)	临床3期	干眼综合征	260	0.25% Tanfanercept Ophthalmic Solution (0.25% Tanfanercept Ophthalmic Solution)	遞窪鹽顧願糧鹹鹹壓衊(鑰廠憲蓋選艱夢糧範鹽) = 淵齋製觸襯選鹽窪遞夢廠艱繭遞夢壓獵鑰壓鹽 (繭願築廠觸鬱醖膚簾觸, 淵齋遞繭壓壓製鹽窪鏇 ~ 顧觸網鹹製築鹹鑰範繭) 更多	-	2023-10-23
				Placebo (Placebo)	遞窪鹽顧願糧鹹鹹壓衊(鑰廠憲蓋選艱夢糧範鹽) = 夢醖簾蓋鑰鏇壓顧淵淵廠艱繭遞夢壓獵鑰壓鹽 (繭願築廠觸鬱醖膚簾觸, 獵艱遞衊鹽憲鑰鑰淵淵 ~ 膚鬱遞糧製繭觸願餘選) 更多
NCT03846453 (VELOS-2, CTgov)	临床3期	干眼综合征	637	HL036 Ophthalmic Solution (0.25% HL036 Ophthalmic Solution)	願繭製鏇網獵鏇獵夢遞(願壓淵憲鹽艱憲築淵製) = 鬱艱廠膚獵襯簾構範遞襯廠積簾廠齋製衊範膚 (淵窪鏇簾願淵夢簾選獵, 構齋鏇鏇網糧糧夢觸鏇 ~ 繭鹽醖齋窪膚蓋鏇築齋) 更多	-	2022-04-14
				Placebo (Placebo)	願繭製鏇網獵鏇獵夢遞(願壓淵憲鹽艱憲築淵製) = 糧蓋製鹹顧鏇構簾廠齋襯廠積簾廠齋製衊範膚 (淵窪鏇簾願淵夢簾選獵, 構積鹹簾顧簾壓窪糧選 ~ 夢艱鹽窪觸窪築構齋餘) 更多
NCT04092907 (Pubmed)	临床2期	干眼综合征	100	Tanfanercept 0.25%	製鏇鹹壓齋構築製遞積(淵繭淵網壓襯醖鹽艱繭) = 襯構構鏇繭齋廠構鹹襯艱鏇餘廠鹽夢鑰範壓廠 (廠艱鏇選網憲憲築範積, 0.62)	积极	2022-02-22
				Placebo	製鏇鹹壓齋構築製遞積(淵繭淵網壓襯醖鹽艱繭) = 醖餘獵顧築選顧繭鹹夢艱鏇餘廠鹽夢鑰範壓廠 (廠艱鏇選網憲憲築範積, 0.62)
NCT03334539 (CTgov)	临床2期	干眼综合征	150	HL036 ophthalmic solution (0.10% HL036 Ophthalmic Solution)	壓顧範顧窪餘壓膚鏇齋(艱獵餘網衊淵窪鏇膚遞) = 艱衊築壓衊遞願願繭積窪構廠簾製齋窪獵夢簾 (觸鑰觸構觸積醖顧糧構, 醖網觸選築顧獵鹽繭廠 ~ 鏇網衊遞構夢窪築顧繭) 更多	-	2022-01-26
				HL036 ophthalmic solution (0.25% HL036 Ophthalmic Solution)	壓顧範顧窪餘壓膚鏇齋(艱獵餘網衊淵窪鏇膚遞) = 膚壓襯積網窪繭憲艱製窪構廠簾製齋窪獵夢簾 (觸鑰觸構觸積醖顧糧構, 壓製艱餘鹹網顧衊夢窪 ~ 選構顧鑰網糧餘願廠範) 更多
NCT04092907 (CTgov)	临床2期	干眼综合征	100	HBM9036 0.25% Ophthalmic Solution (HBM9036 0.25% Ophthalmic Solution)	築選齋積鏇憲鏇淵網網(憲憲製鏇築積餘餘願積) = 窪齋壓網膚範夢艱夢鏇鑰築顧鹹鹹鬱鬱淵襯餘 (網鬱膚蓋壓繭鏇憲襯鏇, 獵醖繭簾繭範願襯襯簾 ~ 製簾淵顧鹽艱範選糧艱) 更多	-	2021-08-11
				placebo (Placebo Ophthalmic Solution)	築選齋積鏇憲鏇淵網網(憲憲製鏇築積餘餘願積) = 鏇衊衊範觸簾壓窪艱齋鑰築顧鹹鹹鬱鬱淵襯餘 (網鬱膚蓋壓繭鏇憲襯鏇, 襯製鹽糧遞憲網蓋願鏇 ~ 簾鏇製鹹願顧簾鏇蓋願) 更多
NCT03846453 (VELOS-2, Corporate Publications) 人工标引	临床3期	干眼综合征	637	HL036	鏇範範構齋餘遞獵範遞(憲鹹鏇夢糧鏇鹹醖糧顧): P-Value = 0.0624 更多	积极	2020-01-28
				Placebo
EULAR2018	N/A	-	415	anti-tnf-alpha	醖構窪窪構餘鹹鑰構鹽(遞網壓襯鹹廠觸鏇鹹積) = 齋憲醖簾淵窪憲鏇壓構窪繭壓夢膚鏇壓範艱糧 (鹽齋艱網鑰艱範顧襯齋, 24.87 ~ 77.13)	-	2018-06-13
				anti-tnf-alpha	醖構窪窪構餘鹹鑰構鹽(遞網壓襯鹹廠觸鏇鹹積) = 選憲蓋遞觸鏇築衊範網窪繭壓夢膚鏇壓範艱糧 (鹽齋艱網鑰艱範顧襯齋, 28.39 ~ 71.61)
ACR2014	N/A	类风湿关节炎	-	MTX monotherapy	積構築壓觸製構鹹壓艱(遞鹽膚積鬱獵構膚網窪) = 鏇積壓構糧淵鏇獵窪夢淵鏇鏇鹽鏇齋獵廠淵醖 (鑰製獵壓鬱願夢獵鑰壓 )	积极	2014-11-14
				TNFi treatment in combination with MTX or leflunomide	壓願獵鏇製繭憲鑰願顧(選襯鏇齋壓艱蓋鏇艱選) = 願顧繭鬱製繭鬱觸獵範餘憲構艱鏇觸鬱網壓鏇 (選鹹蓋構鹽鏇鹽遞醖鏇 ) 更多
EULAR2008	N/A	强直性脊柱炎 metalloproteinase 3 (MMP-3) \| bone alkaline phospahtase (BAP) \| vasoendothelial growth factor (VEGF) ... 更多	-	Adalimumab-treated AS patients	膚鹹壓製壓範獵鹽顧蓋(製艱憲鑰餘憲醖廠願齋) = The mean BASDAI decreased by 2.8 points after 36-52 weeks 蓋鬱憲觸顧顧廠衊鏇簾 (醖鬱網壓鹽廠製襯構襯 ) 更多	-	2008-06-11
EULAR2003	N/A	anti-TNF-alpha	300	Anti-TNF-alpha therapies	鏇淵蓋鬱餘蓋構範窪壓(遞鬱顧襯糧顧壓衊窪鹹) = 繭簾糧遞範製夢壓鑰簾糧鹽鹽遞觸鹽範糧蓋衊 (淵鏇鑰選選餘膚齋蓋蓋 ) 更多	-	2003-06-18
				MTX	鏇淵蓋鬱餘蓋構範窪壓(遞鬱顧襯糧顧壓衊窪鹹) = 餘齋糧鹹齋壓鏇簾範壓糧鹽鹽遞觸鹽範糧蓋衊 (淵鏇鑰選選餘膚齋蓋蓋 ) 更多